You spent the last four weeks getting testosterone reproducible — same dose, same days, same sites, trough labs pulled and read. Now total T sits mid-700s to low-900s, free T is in range, E2 isn't crashing, hematocrit hasn't drifted past 52, and your sleep, libido, and morning erections have stopped being a referendum on yesterday. That's the platform. Weeks 5–10 layer a nighttime GH-secretagogue stack on top of it — not to push more anabolism through a separate channel, but to recruit a second hormonal axis you've already partially restored by fixing testosterone. CJC-1295 + Ipamorelin doesn't replace GH. It tells your own pituitary to fire its natural pulses harder and cleaner, on the timetable evolution actually wired you for: deep, slow-wave sleep.
What's actually happening at the cellular level
Growth hormone is released in pulses, not as a tonic. The biggest pulse of your day fires within the first 60–90 minutes of slow-wave sleep, and that pulse is what drives overnight IGF-1 synthesis in the liver, mitotic activity in fibroblasts, lipolysis in adipocytes, and the connective-tissue remodeling you feel as "I slept hard and woke up not stiff." Decades of normal aging blunt that pulse. TRT optimizes the androgen axis but does nothing direct for GH — which is why a 45-year-old man with perfect TRT labs still doesn't recover or sleep like he did at 25.
CJC-1295 and Ipamorelin act on two different receptors that converge on the same outcome. CJC-1295 is a GHRH analog — it binds the GHRH receptor on pituitary somatotrophs and raises the baseline of pulse amplitude. Ipamorelin is a ghrelin-mimetic that binds the GHSR receptor (the same one ghrelin uses) and triggers an acute, sharp pulse on top of that elevated baseline. Stacked, you get sustained baseline plus pulsatile spikes — the substrate calls this combination "the gold standard," with synergistic GH release that neither compound produces alone.
The reason this matters more than running either alone: Ipamorelin is the cleanest ghrelin-mimetic in the class. Substrate is explicit — "no cortisol or prolactin spillover," unlike GHRP-2 or GHRP-6 which drag cortisol and prolactin up alongside GH. You get the anabolic and lipolytic signal without the appetite blowout or stress-hormone tail. And because both compounds work through your pituitary rather than bypassing it, the pulsatile pattern is preserved. There is no negative feedback shutdown the way exogenous recombinant HGH causes. You can cycle off and your axis returns to baseline within weeks.
CJC-1295 comes in two forms: with DAC (drug affinity complex — half-life 8+ days, dosed weekly) and without DAC (modified GRF 1-29 — half-life under 30 minutes, dosed multiple times daily). For a six-week build on top of TRT, the weekly DAC version is the substrate-preferred path: one injection sets your baseline for the week, then Ipamorelin does the pulsing nightly. Less injection burden, identical IGF-1 trajectory.
The Weeks 5–10 stack
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| Testosterone Cypionate (continued from Phase 1) | Your established Phase 1 dose | IM or SubQ | 2x/week (Mon/Thu) | 🔵 Clinical | Do not adjust during this layering window. Hold dose constant so you can attribute changes to the GH stack. |
| CJC-1295 with DAC | 2 mg | SubQ | 1x/week | 🟢 Expert | Any day, any time — 8+ day half-life makes timing irrelevant. Substrate-cited as the baseline-setting compound. |
| Ipamorelin | 200–300 mcg | SubQ | 1x nightly, before bed | 🟢 Expert | Empty stomach. Minimum 2 hours after last meal. Stacks with your natural slow-wave-sleep GH pulse. |
| hCG or Gonadorelin (continued from Phase 1, if running) | Your established dose | SubQ | 2–3x/week | 🟢 Expert | Maintain through the GH layer. No interaction with CJC/Ipa. |
Critical fasted-state rule, substrate-cited: food — especially carbs and fat — within 30 minutes of an Ipamorelin injection blunts the GH pulse by 50–80%. The pulse is killed by insulin and elevated free fatty acids. You inject Ipamorelin a minimum of two hours after your last meal, then nothing but water until morning. If you eat dinner at 8 pm, Ipamorelin fires no earlier than 10. If you eat at 9, push it to 11 or skip the night. There is no useful middle ground — a fed-state injection is a wasted injection.
Reconstitution: CJC-1295 DAC at 2 mg/vial with 2 mL bacteriostatic water yields 1 mg/mL — draw 0.2 mL for a 2 mg dose. Ipamorelin at 5 mg/vial with 2.5 mL BAC water yields 2 mg/mL — draw 0.10–0.15 mL for a 200–300 mcg dose. Use insulin syringes, 29–31 gauge, 5/16". SubQ into abdominal fat at least 2 inches from the navel; rotate sites nightly.
What you should feel, week by week
- Week 5 (first week of stack) — sleep deepens within 3–5 nights. Substrate is consistent on this: Ipamorelin's strongest acute signal is in slow-wave sleep architecture. You wake less, dream more vividly toward morning, and recovery from training feels disproportionate to your dose.
- Week 6 — skin texture begins to shift. Practitioner consensus puts visible skin changes at 4–8 weeks; expect early signals here.
- Week 7–8 — connective tissue recovery noticeably faster. Joint glide returns. Old strain sites stop announcing themselves. Body composition begins to shift — abdominal fat down, fullness up — even at constant calories.
- Week 9–10 — the IGF-1 retest at week 10 is what tells you whether the stack is working. Substrate-cited expected response: meaningful baseline IGF-1 rise, generally toward the upper third of age-adjusted reference range. If your week-10 IGF-1 hasn't moved from baseline by at least 30–50%, your fasted-state discipline is the first thing to audit, not your dose.
What's NOT happening yet
- You are not getting "GH-user" results. This is pituitary-mediated. Pulse amplitudes are higher; you are not running 4 IU/day of exogenous recombinant HGH. Anyone selling the stack as "the same as HGH but legal" is misframing the mechanism.
- No HPTA shutdown from the GH stack. CJC and Ipa do not suppress LH/FSH or testosterone. The TRT-driven shutdown you're already managing with hCG/gonadorelin is not worsened by adding the GH layer.
- Fasting glucose may drift up 5–10 mg/dL. GH is counter-regulatory to insulin. Substrate flags this explicitly — track fasting glucose at week 8 and week 10. If fasting insulin was already >8 at Phase 1 baseline, the GH layer is contraindicated until insulin sensitivity is restored.
- Water retention in the first 10–14 days is real but transient. Mild ankle/finger puffiness is a known early signal of GH activity, not edema. It resolves as the body adapts.
- Appetite does not blow out. That's the Ipamorelin selection at work — substrate is explicit that Ipamorelin lacks the appetite-driving signal of GHRP-6 or GHRP-2. If you're suddenly ravenous, recheck what you're actually injecting.
- You are not on this stack forever. Substrate-cited cycle length: 8–12 weeks on, then a 4-week washout before re-running. Continuous dosing past 12 weeks blunts pulse amplitude as the receptor desensitizes. Weeks 5–10 is a six-week run that ends cleanly at week 10.
Labs to pull at week 10: IGF-1 (the only reliable proxy for whether the stack is doing what it's supposed to do), fasting glucose and insulin (catch the counter-regulatory drift early), and your standard TRT panel (total T, free T, E2, hematocrit) to confirm the platform held while you layered.
The substrate describes this protocol with conviction. Track your IGF-1, your fasted-state discipline, and your week-10 numbers — then decide what the next six weeks look like.